References
- Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007;448:427-34. https://doi.org/10.1038/nature06005
- Markowitz J, Hyams J, Mack D, Leleiko N, Evans J, Kugathasan S, et al. Corticosteroid therapy in the age of infliximab: acute and 1-year outcomes in newly diagnosed children with Crohn's disease. Clin Gastroenterol Hepatol 2006;4:1124-9. https://doi.org/10.1016/j.cgh.2006.05.011
- Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-35. https://doi.org/10.1056/NEJM199710093371502
- Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-405. https://doi.org/10.1056/NEJM199905063401804
- Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9. https://doi.org/10.1016/S0140-6736(02)08512-4
- Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004;126:402-13. https://doi.org/10.1053/j.gastro.2003.11.014
- Cezard JP, Nouaili N, Talbotec C, Hugot JP, Gobert JG, Schmitz J, et al. A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (Remicade) in severe pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2003;36:632-6. https://doi.org/10.1097/00005176-200305000-00007
- Baldassano R, Braegger CP, Escher JC, DeWoody K, Hendricks DF, Keenan GF, et al. Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease. Am J Gastroenterol 2003;98:833-8. https://doi.org/10.1111/j.1572-0241.2003.07343.x
- Stephens MC, Shepanski MA, Mamula P, Markowitz JE, Brown KA, Baldassano RN. Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center. Am J Gastroenterol 2003;98:104-11. https://doi.org/10.1111/j.1572-0241.2003.07161.x
- Hyams JS, Lerer T, Griffiths A, Pfefferkorn M, Kugathasan S, Evans J, et al. Long-term outcome of maintenance infliximab therapy in children with Crohn's disease. Inflamm Bowel Dis 2009;15:816-22. https://doi.org/10.1002/ibd.20845
- Yang SK, Yun S, Kim JH, Park JY, Kim HY, Kim YH, et al. Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986-2005: a KASID study. Inflamm Bowel Dis 2008;14:542-9. https://doi.org/10.1002/ibd.20310
- Inoue N, Tamura K, Kinouchi Y, Fukuda Y, Takahashi S, Ogura Y, et al. Lack of common NOD2 variants in Japanese patients with Crohn's disease. Gastroenterology 2002;123:86-91. https://doi.org/10.1053/gast.2002.34155
- Hsiao CH, Wei SC, Wong JM, Lai HS, Chang MH, Ni YH. Pediatric Crohn disease: clinical and genetic characteristics in Taiwan. J Pediatr Gastroenterol Nutr 2007;44:342-6. https://doi.org/10.1097/MPG.0b013e31802c6997
- Wang YF, Zhang H, Ouyang Q. Clinical manifestations of inflammatory bowel disease: East and West differences. J Dig Dis 2007;8:121-7. https://doi.org/10.1111/j.1443-9573.2007.00296.x
- Van Limbergen J, Russell RK, Drummond HE, Aldhous MC, Round NK, Nimmo ER, et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology 2008;135:1114-22. https://doi.org/10.1053/j.gastro.2008.06.081
- Rutgeerts PJ. Review article: the limitations of corticosteroid therapy in Crohn's disease. Aliment Pharmacol Ther 2001;15:1515-25. https://doi.org/10.1046/j.1365-2036.2001.01060.x
- Summers RW, Switz DM, Sessions JT Jr, Becktel JM, Best WR, Kern F Jr, et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979;77:847-69.
- Malchow H, Ewe K, Brandes JW, Goebell H, Ehms H, Sommer H, et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984;86:249-66.
- Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994;35:360-2. https://doi.org/10.1136/gut.35.3.360
- Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001;121:255-60. https://doi.org/10.1053/gast.2001.26279
- Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Chen DM, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006;4:621-30. https://doi.org/10.1016/j.cgh.2006.03.002
- Singleton JW, Law DH, Kelley ML Jr, Mekhjian HS, Sturdevant RA. National Cooperative Crohn's Disease Study: adverse reactions to study drugs. Gastroenterology 1979;77:870-82.
- Lichtenstein GR. Approach to corticosteroid-dependent and corticosteroid- refractory Crohn's disease. Inflamm Bowel Dis 2001;7 Suppl 1:S23-9. https://doi.org/10.1002/ibd.3780070506
- Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007;132:863-73; quiz 1165-6. https://doi.org/10.1053/j.gastro.2006.12.003
- de Ridder L, Benninga MA, Taminiau JA, Hommes DW. Infliximab as first-line therapy in severe pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2006;43:388-90. https://doi.org/10.1097/01.mpg.0000226369.31956.bf
- Akobeng AK, Zachos M. Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2004:CD003574.
- Behm BW, Bickston SJ. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2008:CD006893.
- D'Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008;371:660-7 https://doi.org/10.1016/S0140-6736(08)60304-9
- Lindsay J, Punekar YS, Morris J, Chung-Faye G. Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn's disease--modelling outcomes in active luminal and fistulizing disease in adults. Aliment Pharmacol Ther 2008;28:76-87. https://doi.org/10.1111/j.1365-2036.2008.03709.x
- Geboes K, Rutgeerts P, Opdenakker G, Olson A, Patel K, Wagner CL, et al. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Curr Med Res Opin 2005;21:1741-54. https://doi.org/10.1185/030079905X65457
- Markowitz J, Grancher K, Kohn N, Lesser M, Daum F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000;119:895-902. https://doi.org/10.1053/gast.2000.18144
- Hyams JS, Markowitz J, Wyllie R. Use of infliximab in the treatment of Crohn's disease in children and adolescents. J Pediatr 2000;137:192-6. https://doi.org/10.1067/mpd.2000.107161
- Friesen CA, Calabro C, Christenson K, Carpenter E, Welchert E, Daniel JF, et al. Safety of infliximab treatment in pediatric patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2004;39:265-9. https://doi.org/10.1097/00005176-200409000-00008
- Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Bijl H, et al. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 1994;344:1125-7. https://doi.org/10.1016/S0140-6736(94)90632-7
- Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of antitumor necrosis factor alpha monoclonal antibody combined with lowdose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63. https://doi.org/10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W
- Baecklund E, Ekbom A, Sparen P, Feltelius N, Klareskog L. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ 1998;317:180-1.
- Burger DC, Florin TH. Hepatosplenic T-cell lymphoma following infliximab therapy for Crohn's disease. Med J Aust 2009;190:341-2.
- Zeidan A, Sham R, Shapiro J, Baratta A, Kouides P. Hepatosplenic T-cell lymphoma in a patient with Crohn's disease who received infliximab therapy. Leuk Lymphoma 2007;48:1410-3. https://doi.org/10.1080/10428190701345433
- Kim MJ, Lee JS, Lee JH, Kim JY, Choe YH. Infliximab therapy in children with Crohn's disease: A one-year evaluation of efficacy comparing 'top-down' and 'step-up' strategies. Acta Paediatr 2010 Jul 7(Epub ahead of print)
- Lee JS, Lee JH, Lee HJ, Kim MJ, Choe YH. Efficacy of early treatment with infliximab in pediatric Crohn's disease. World J Gastroenterol 2010;16:1776-81. https://doi.org/10.3748/wjg.v16.i14.1776
Cited by
- Inflammatory Bowel Disease in Pediatric Age vol.14, pp.suppl1, 2010, https://doi.org/10.5223/kjpgn.2011.14.suppl1.s34
- Efficacy of Early Infliximab Treatment for Pediatric Crohn's Disease: A Three-year Follow-up vol.15, pp.4, 2010, https://doi.org/10.5223/pghn.2012.15.4.243
- Pyruvate Kinase M2 Regulates Apoptosis of Intestinal Epithelial Cells in Crohn’s Disease vol.60, pp.2, 2015, https://doi.org/10.1007/s10620-014-3189-0
- Reflections on treatment of IBD in children and adolescents vol.40, pp.6, 2018, https://doi.org/10.1080/08923973.2018.1474922